CDC42抑制剂CASIN对食管癌细胞活力与迁移能力的抑制作用

doi:10.3969/j.issn.1004-616x.2021.02.009

Abstract

Abstract: OBJECTIVE: To investigate effects of CASIN,a specific cell division circle 42 (CDC42) inhibitor,on viability,migration and pseudopodia of esophageal cancer cells,and its mechanism of inducing apoptosis. METHODS: According to expression of the CDC42 protein,four groups were set up:endogenous CDC42 high/low expression groups and exogenous CDC42 high/low expression groups. Western blot was used to detect expression of endogenous CDC42 protein in 9 esophageal cancer cell lines. From the analyses,two endogenous high-expression and two low-expression esophageal cancer cell lines were selected. Cell viability assay was used to detect the effect of CASIN on cell viability. Wound healing assay was to detect cell invasion. Western blot was to detect protein expression levels of Caspases-3 and PARP. After constructed the Flag-CDC42 and GFP-CDC42 plasmid successfully,they were transfected into esophageal cancer cells to distinguish exogenous CDC42 high/low expression groups. Cell viability assay and wound healing assay were used as described above. Furthermore,the immunofluorescence experiment was used to detect effects of CASIN on pseudopodia formation. RESULTS: In the endogenous CDC42 high/low expression groups,our data show that CASIN at concentrations of 15-30 μmol/L significantly inhibited cell viability and cell invasion (P<0.05),and increased the expression of Caspase-3 and lyse PARP. The latter suggests that CASIN might induce cell apoptosis. Compared with the exogenous CDC42 low expression group,20 μmol/L CASIN significantly reduced expression in the exogenous CDC42 high expression group (P<0.05). In addition,data from the immunofluorescence experiments show that CASIN suppressed the effect of CDC42 in promoting the formation of pseudopodia. CONCLUSION: CASIN reduced the viability and migration of esophageal cancer cells,inhibit pseudopodia,and induce cell apoptosis in vitro. Therefore,CASIN can be developed further as a new targeted drug against esophageal cancer.

Key words: CDC42, CASIN, esophageal cancer, inhibition

CLC Number:

R735.1

CHEN Wanxian, WANG Simeng, CHEN Zhangyu, WANG Panji, ZHENG Chunwen, LI Enmin, XU Liyan. CASIN, a CDC42 inhibitor, inhibited viability and migration of esophageal carcinoma cells in vitro[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 136-142.

References

[1] ALSOP B R, SHARMA P. Esophageal Cancer[J]. Gastroenterol Clin North Am, 2016, 45(3):399-412.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] LIN Y, TOTSUKA Y, SHAN B, et al. Esophageal cancer in high-risk areas of China:research progress and challenges[J]. Ann Epidemiol, 2017, 27(3):215-221.
[4] RIDLEY A J. Rho GTPase signalling in cell migration[J]. Curr Opin Cell Biol, 2015, 36:103-112.
[5] STENGEL K, ZHENG Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis[J]. Cell Signal, 2011, 23(9):1415-1423.
[6] ZHOU X, FLORIAN M C, ARUMUGAM P, et al. RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitors[J]. J Exp Med, 2013, 210(11):2371-2385.
[7] LOIRAND G. Rho kinases in health and disease:from basic science to translational research[J]. Pharmacol Rev, 2015, 67(4):1074-1095.
[8] LI H, PEYROLLIER K, KILIC G, et al. Rho GTPases and cancer[J]. Biofactors, 2014, 40(2):226-235.
[9] QADIR M I, PARVEEN A, ALI M. Cdc42:role in cancer management[J]. Chem Biol Drug Des, 2015, 86(4):432-439.
[10] FLORIAN M C, DÖRR K, NIEBEL A, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation[J]. Cell Stem Cell, 2012, 10(5):520-530.
[11] PETERSON J R, LEBENSOHN A M, PELISH H E, et al. Biochemical suppression of small-molecule inhibitors:a strategy to identify inhibitor targets and signaling pathway components[J]. Chem Biol, 2006, 13(4):443-452.
[12] SWAINE T, DITTMAR M T. CDC42 use in viral cell entry processes by RNA viruses[J]. Viruses, 2015, 7(12):6526-6536.
[13] YANG J Q, KALIM K W, LI Y, et al. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation[J]. Clin Exp Allergy, 2019, 49(1):92-107.
[14] KUMAR P, NAGARAJAN A, UCHIL P D. Analysis of cell viability by the MTT assay[J]. Cold Spring Harb Protoc, 2018, 2018(6):1101.
[15] ROEDER F, NICOLAY N H, NGUYEN T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer[J]. Radiat Oncol, 2014, 9:191.
[16] KATO H, NAKAJIMA M. Treatments for esophageal cancer:a review[J]. Gen Thorac Cardiovasc Surg, 2013, 61(6):330-335.
[17] HARADA K, POOL P M, BABA H, et al. Cancer stem cells in esophageal cancer and response to therapy[J]. Cancer, 2018, 124(20):3962-3964.
[18] HOU X B, WEN J X, REN Z P, et al. Non-coding RNAs:new biomarkers and therapeutic targets for esophageal cancer[J]. Oncotarget, 2017, 8(26):43571-43578.
[19] LEE S, CRAIG B T, ROMAIN C V, et al. Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation[J]. Cancer Lett, 2014, 355(2):210-216.
[20] WANG X, XU W, ZHAN P, et al. Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma[J]. J Cell Mol Med, 2018, 22(4):2177-2189.
[21] ZHANG Y, LI J, LAI X N, et al. Focus on Cdc42 in breast cancer:new insights, target therapy development and non-coding RNAs[J]. Cells, 2019, 8(2):E146.

CASIN, a CDC42 inhibitor, inhibited viability and migration of esophageal carcinoma cells in vitro

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan. Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 124-128.
[2]	LIN Kaihuang, CAI Gaoyang, LIU Xincheng. Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 448-451.
[3]	FENG Min, ABBIE·Mohetar, SHI Jingyi, ZUKELAI·Alijiang, LI Yongxiang, YAN Changshun, LI Xiumei. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 29-32.
[4]	MA Lili, ZHANG Shuli, LI Qin, XU Peng, FENG Min, LI Xiumei. Screening and identification of differentially expressed miRNAs in esophageal cancers among Xinjiang Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 52-56.
[5]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[6]	HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.
[7]	QI Xuesong, LI Ning, WANG Chunyan, TONG Peng, GOU Qiao, ZHENG Hui. Effect of vinorelbine tartrate lipid microsphere injection on growth of human breast cancer cells in nude mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 103-106.
[8]	LI Xiumei, GUO Qiong, WANG Dong, CHEN Yan, LI Hui, CHEN Hongming, LI Huiwu. Expression and significance of miR-143, MMP-2 and TIMP-1 in esophageal cancer in Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 32-35,40.
[9]	CAO Ying-ya，CHE Yi-qun，CHEN Qun，MA Wen-tao，LIU Yang，HAO Jia-jie，CAI Yan，LU Wei-hua，WANG Ming-rong，ZHANG Yu. Establishment of an esophageal cell line with stable expression of inducible PLK1-shRNA [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(5): 348-352.
[10]	LI Xiu-mei，LI Hui，JIANG Xiao-fang，CHEN Yan，CHEN Hong-ming，LI Hui-wu. Expression of Survivin shRNA interference on CDK4 in esophageal ECA109 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(4): 298-304.
[11]	TIAN Wei，ZHANG Hui-xia，CHEN Yan. Methylation of the CpG island in MT-3 gene in esophageal carcinoma in Kazaks and Hans in Xinjiang [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(5): 357-359.
[12]	CHEN Lan-ying，SONG Wei，YANG Hai-bo，YU Huai-bin，LIU Ya-jun，ZHI Shuang-cheng，YANG Feng. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(3): 201-204.
[13]	. Expressions and correlations of Livin and c-IAP2 in the Xinjiang Uygurs esophageal carcinoma [J]. , 2012, 24(2): 125-128.
[14]	LI Lei，DENG Yan-chao，ZHAO Yan，CHEN Yan. Methylation of the FHIT gene in esophageal carcinoma in Kazakh and Han and relationship with prognosis [J]. , 2012, 24(2): 132-135.
[15]	DU Ze-sen，WU Zhi-yong，ZHENG Chun-peng，LI Zhuo-yi，FU Jun-hui. Prognostic significance of the number of negative lymph node on the survival of patients with thoracic esophageal cancer [J]. , 2012, 24(1): 64-67.